Creative Medical Technology (NASDAQ:CELZ) Issues Earnings Results, Beats Expectations By $0.01 EPS

Creative Medical Technology (NASDAQ:CELZ) issued its quarterly earnings results on Friday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01, Zacks reports.

Creative Medical Technology Stock Performance

Shares of CELZ stock opened at $2.31 on Friday. The stock’s fifty day moving average price is $2.05 and its two-hundred day moving average price is $2.32. The company has a market cap of $8.55 million, a PE ratio of -0.89 and a beta of 1.87. Creative Medical Technology has a fifty-two week low of $1.50 and a fifty-two week high of $6.25.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC bought a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.